

Antoine Thiery-vuillemin

List of Publications by Citations

Source: <https://exaly.com/author-pdf/871894/antoine-thiery-vuillemin-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

138 papers	5,685 citations	33 h-index	73 g-index
157 ext. papers	7,622 ext. citations	5.1 avg, IF	5.38 L-index

#	Paper	IF	Citations
138	2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2737-47		1636
137	Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1340-9	2.4	444
136	Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018 , 379, 417-427	59.2	416
135	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1151-1159	2.4	344
134	Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3189-3197	2.2	168
133	ImmunoChip analysis identifies multiple susceptibility loci for systemic sclerosis. <i>American Journal of Human Genetics</i> , 2014 , 94, 47-61	11	151
132	Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1804-14	0.7	123
131	Genome-wide DNA methylation analysis in dermal fibroblasts from patients with diffuse and limited systemic sclerosis reveals common and subset-specific DNA methylation aberrancies. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1612-20	2.4	115
130	Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - Report from OMERACT CTD-ILD Working Group. <i>Journal of Rheumatology</i> , 2015 , 42, 2168-71	4.1	99
129	Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1975-88	27.4	74
128	Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. <i>Arthritis Research and Therapy</i> , 2015 , 17, 372	5.7	61
127	Feasibility and construct validity of PROMIS and "legacy" instruments in an academic scleroderma clinic. <i>Value in Health</i> , 2012 , 15, 128-34	3.3	59
126	Cardiac arrhythmias and conduction defects in systemic sclerosis. <i>Rheumatology</i> , 2014 , 53, 1172-7	3.9	58
125	Treatment of acute gout: a systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2014 , 44, 31-8	5.3	56
124	Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2014 , 44, 55-62	5.3	56
123	NEDD9 targets to promote endothelial fibrosis and pulmonary arterial hypertension. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	52
122	Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription. <i>American Journal of Physiology - Cell Physiology</i> , 2014 , 307, C2-13	5.4	52

121	Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) definition. <i>Journal of Scleroderma and Related Disorders</i> , 2017 , 2, 115-120 ^{2,3}	49
120	Management of gastrointestinal involvement in scleroderma. <i>Current Treatment Options in Rheumatology</i> , 2015 , 1, 82-105	1.3 48
119	Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II. <i>Annals of the American Thoracic Society</i> , 2018 , 15, 1286-1295	4.7 48
118	Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis. <i>Journal of Clinical Investigation</i> , 2020 , 130, 2451-2464	15.9 47
117	Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 3695-3702	11.5 44
116	Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 648-656	2.4 43
115	Antinuclear antibody-negative systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2015 , 44, 680-6	5.3 43
114	Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 201, 650-660	10.2 41
113	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. <i>Journal of Clinical Epidemiology</i> , 2014 , 67, 706-14	5.7 40
112	Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. <i>Journal of Rheumatology</i> , 2011 , 38, 1920-4	4.1 40
111	Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 724-726	2.4 38
110	Old medications and new targeted therapies in systemic sclerosis. <i>Rheumatology</i> , 2015 , 54, 1944-53	3.9 36
109	Establishing clinical severity for PROMIS measures in adult patients with rheumatic diseases. <i>Quality of Life Research</i> , 2018 , 27, 755-764	3.7 35
108	Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease. <i>Rheumatology</i> , 2019 , 58, 567-579	3.9 35
107	Systemic Sclerosis Trial Design Moving Forward. <i>Journal of Scleroderma and Related Disorders</i> , 2016 , 1, 177-180	2.3 34
106	Hand Impairment in Systemic Sclerosis: Various Manifestations and Currently Available Treatment. <i>Current Treatment Options in Rheumatology</i> , 2016 , 2, 252-269	1.3 33
105	Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 379-386 ^{2,4}	33
104	Clinical impact of targeted therapies in patients with metastatic clear-cell renal cell carcinoma. <i>OncoTargets and Therapy</i> , 2014 , 7, 365-74	4.4 32

103	Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 204, 209-221	10.2	30
102	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 618-625	2.4	30
101	Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1367-71	2.4	29
100	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. <i>Journal of Rheumatology</i> , 2019 , 46, 721-726	4.1	29
99	Responsiveness to Change and Minimally Important Differences of the Patient-Reported Outcomes Measurement Information System Gastrointestinal Symptoms Scales. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 1186-1192	4	27
98	Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. <i>Rheumatology</i> , 2015 , 54, 144-51	3.9	27
97	The patient experience of Raynaud's phenomenon in systemic sclerosis. <i>Rheumatology</i> , 2019 , 58, 18-26	3.9	26
96	A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1600-1607	2.4	25
95	Methyl-CpG-binding protein 2 mediates antifibrotic effects in scleroderma fibroblasts. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1208-1218	2.4	25
94	Impact of the revised haemodynamic definition on the diagnosis of pulmonary hypertension in patients with systemic sclerosis. <i>European Respiratory Journal</i> , 2019 , 54,	13.6	24
93	and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 552-562	11.5	23
92	Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARIUS study. <i>ESMO Open</i> , 2018 , 3, e000397	6	23
91	A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift. <i>Postgraduate Medicine</i> , 2016 , 128, 34-40	3.7	22
90	Scleroderma dermal microvascular endothelial cells exhibit defective response to pro-angiogenic chemokines. <i>Rheumatology</i> , 2016 , 55, 745-54	3.9	21
89	Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARIUS Study. <i>European Urology</i> , 2020 , 77, 380-387	10.2	20
88	Activation of the Thromboxane A2 Receptor by 8-Isoprostane Inhibits the Pro-Angiogenic Effect of Vascular Endothelial Growth Factor in Scleroderma. <i>Journal of Investigative Dermatology</i> , 2015 , 135, 3153-3162 ¹⁹	4.3	19
87	Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1242-1248	2.4	18
86	Health-related quality of life and treatment satisfaction in patients with gout: results from a cross-sectional study in a managed care setting. <i>Patient Preference and Adherence</i> , 2015 , 9, 971-81	2.4	18

85	Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge?. <i>European Urology</i> , 2020 , 77, 761-763	10.2	18
84	Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 48, 1059-1067	5.3	18
83	Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 128-132	2.4	17
82	Intestinal pseudo-obstruction in patients with systemic sclerosis: an analysis of the Nationwide Inpatient Sample. <i>Rheumatology</i> , 2016 , 55, 654-8	3.9	17
81	Development of an online library of patient-reported outcome measures in gastroenterology: the GI-PRO database. <i>American Journal of Gastroenterology</i> , 2014 , 109, 234-48	0.7	17
80	Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2015 , 54, 1369-79	3.9	17
79	Impact of National Institutes of Health Gastrointestinal PROMIS Measures in Clinical Practice: Results of a Multicenter Controlled Trial. <i>American Journal of Gastroenterology</i> , 2016 , 111, 1546-1556	0.7	17
78	Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features. <i>RMD Open</i> , 2019 , 5, e000826	5.9	16
77	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1333-1339	2.4	16
76	Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations. <i>PLoS ONE</i> , 2018 , 13, e0189498	3.7	15
75	Screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension: a systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2014 , 43, 536-41	5.3	15
74	Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer. <i>Clinical Medicine Insights: Oncology</i> , 2013 , 7, 1-12	1.8	15
73	Safety profile of new anticancer drugs. <i>Expert Opinion on Drug Safety</i> , 2010 , 9, 301-17	4.1	15
72	Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2018 , 57, 813-817	3.9	14
71	In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy?. <i>Oncologist</i> , 2015 , 20, 344-50	5.7	13
70	Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. <i>Arthritis Research and Therapy</i> , 2016 , 18, 20	5.7	13
69	Efficacy of trabectedin in metastatic solitary fibrous tumor. <i>Rare Tumors</i> , 2011 , 3, e29	1.1	13
68	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial.. <i>Lancet Rheumatology, The</i> , 2020 , 2, e743-e753	14.2	13

67	Identification of Pirin as a Molecular Target of the CCG-1423/CCG-203971 Series of Antifibrotic and Antimetastatic Compounds. <i>ACS Pharmacology and Translational Science</i> , 2019 , 2, 92-100	5.9	12
66	Hemodialysis does not impact axitinib exposure: clinical case of a patient with metastatic renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 79, 1273-1276	3.5	10
65	A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers. <i>Arthritis Research and Therapy</i> , 2019 , 21, 202	5.7	10
64	Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): study protocol. <i>Health and Quality of Life Outcomes</i> , 2019 , 17, 25	3	10
63	An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups. <i>Journal of Scleroderma and Related Disorders</i> , 2019 , 4, 17-27	2.3	10
62	Rheumatoid arthritis-associated interstitial lung disease: Current update on prevalence, risk factors, and pharmacologic treatment. <i>Current Treatment Options in Rheumatology</i> , 2020 , 6, 337-353	1.3	10
61	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	10
60	Performance of Gout Impact Scale in a longitudinal observational study of patients with gout. <i>Rheumatology</i> , 2016 , 55, 982-90	3.9	9
59	Immunomodulatory effects of everolimus in a long responsive patient with metastatic renal cell carcinoma. <i>Journal of Immunotherapy</i> , 2014 , 37, 51-4	5	9
58	Reliability and Validity of the Tender and Swollen Joint Counts and the Modified Rodnan Skin Score in Early Diffuse Cutaneous Systemic Sclerosis: Analysis from the Prospective Registry of Early Systemic Sclerosis Cohort. <i>Journal of Rheumatology</i> , 2017 , 44, 791-794	4.1	8
57	PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS5091-TPS5091	2.2	8
56	Patient-reported outcome instruments in clinical trials of systemic sclerosis.. <i>Journal of Scleroderma and Related Disorders</i> , 2020 , 5, 90-102	2.3	8
55	Treatment for systemic sclerosis-associated interstitial lung disease. <i>Current Opinion in Rheumatology</i> , 2021 , 33, 240-248	5.3	8
54	Targeted and immune therapies among patients with metastatic renal carcinoma undergoing hemodialysis: A systemic review. <i>Seminars in Oncology</i> , 2020 , 47, 103-116	5.5	7
53	Combining molecular targeted therapies: clinical experience. <i>Anti-Cancer Drugs</i> , 2011 , 22, 701-10	2.4	7
52	Longitudinal Assessment of Patient-reported Outcome Measures in Systemic Sclerosis Patients with Gastroesophageal Reflux Disease - Scleroderma Clinical Trials Consortium. <i>Journal of Rheumatology</i> , 2019 , 46, 78-84	4.1	7
51	New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 641-650	2.4	7
50	Insight into the Contrasting Findings of Therapeutic Trials of Digital Ischaemic Manifestations of Systemic Sclerosis. <i>Current Treatment Options in Rheumatology</i> , 2019 , 5, 85-103	1.3	6

49	Calcinosis is associated with ischemic manifestations and increased disability in patients with systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 891-896	5.3	6
48	Metronomic cyclophosphamide therapy in hormone-naïve patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial. <i>Medical Oncology</i> , 2016 , 33, 89	3.7	6
47	Psychometric validation of the Hand Disability in Systemic Sclerosis-Digital Ulcers (HDISS-DU [®]) patient-reported outcome instrument. <i>Arthritis Research and Therapy</i> , 2020 , 22, 3	5.7	6
46	Response to: Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series by Narváz. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e124	2.4	6
45	Points to consider for clinical trials of the gastrointestinal tract in systemic sclerosis. <i>Rheumatology</i> , 2017 , 56, v4-v11	3.9	5
44	Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 231-8	3.3	5
43	Factors Influencing Overall Survival for Patients With Metastatic Clear-Cell Renal-Cell Carcinoma in Daily Practice. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e297-e305	3.3	5
42	Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open Label Extension of a Phase 3 Randomized Controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 ,	10.2	5
41	Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition.. <i>Journal of Scleroderma and Related Disorders</i> , 2022 , 7, 24-32	2.3	5
40	Duration: escalation study of oral etoposide with carboplatin in patients with varied solid tumors. <i>Anti-Cancer Drugs</i> , 2010 , 21, 958-62	2.4	4
39	Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials. <i>Expert Opinion on Emerging Drugs</i> , 2020 , 25, 455-466	3.7	4
38	New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 30, 635-652	5.9	4
37	Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort. <i>Arthritis Research and Therapy</i> , 2021 , 23, 170	5.7	4
36	Fatigue Predicts Future Reduced Social Participation, not Reduced Physical Function or Quality of Life in People with Systemic Sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2021 , 6, 187-193	2.3	4
35	Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2021 , 23, 10	5.7	4
34	Interstitial lung disease in systemic sclerosis quantification of disease classification and progression with high-resolution computed tomography: An observational study.. <i>Journal of Scleroderma and Related Disorders</i> , 2021 , 6, 154-164	2.3	4
33	Health State Utilities and Disease Duration in Systemic Sclerosis: Is There an Association?. <i>Journal of Rheumatology</i> , 2016 , 43, 1832-1837	4.1	3
32	Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma: outcomes from a multicenter US-based systemic sclerosis registry. <i>Clinical Rheumatology</i> , 2020 , 39, 93-102	3.9	3

31	A Randomized Controlled Trial of Acupressure for the Treatment of Raynaud's Phenomenon: The difficulty of conducting a trial in Raynaud's phenomenon. <i>Journal of Scleroderma and Related Disorders</i> , 2016 , 1, 226-233	2.3	3
30	Patient perception of disease burden in diffuse cutaneous systemic sclerosis.. <i>Journal of Scleroderma and Related Disorders</i> , 2020 , 5, 66-76	2.3	3
29	How do patients define Raynaud's phenomenon? Differences between primary and secondary disease. <i>Clinical Rheumatology</i> , 2021 , 40, 1611-1616	3.9	3
28	Anticancer therapy in patients with porphyrias: evidence today. <i>Expert Opinion on Drug Safety</i> , 2008 , 7, 159-65	4.1	2
27	Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.. <i>Lancet Oncology</i> , 2022	21.7	2
26	Activity and tolerability of maintenance avelumab immunotherapy after first line polychemotherapy including platinum in patients with locally advanced or metastatic squamous cell penile carcinoma: PULSE. <i>Bulletin Du Cancer</i> , 2020 , 107, eS16-eS21	2.4	2
25	Assessment of skin disease in scleroderma: Practices and opinions of investigators studying scleroderma.. <i>Journal of Scleroderma and Related Disorders</i> , 2020 , 5, 167-171	2.3	2
24	Integrating new therapies for systemic sclerosis-associated lung fibrosis in clinical practice. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 560-562	35.1	2
23	Economic Burden of Metastatic Clear-Cell Renal Cell Carcinoma for French Patients Treated With Targeted Therapies. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e227-e234	3.3	2
22	Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. <i>Journal of Scleroderma and Related Disorders</i> , 2021 , 6, 66-76	2.3	2
21	Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies. <i>Clinical Reviews in Allergy and Immunology</i> , 2021 , 1	12.3	2
20	Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography. <i>Journal of Scleroderma and Related Disorders</i> , 2021 , 6, 66-76	2.3	1
19	Symptom experience of limited cutaneous systemic sclerosis from the Patients' perspective: A qualitative study. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 52, 151926-151926	5.3	1
18	Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis.. <i>Arthritis Research and Therapy</i> , 2022 , 24, 19	5.7	1
17	Intensive and app-delivered occupational therapy to improve upper extremity function in early diffuse cutaneous systemic sclerosis: a pilot two-arm trial. <i>Rheumatology</i> , 2021 , 60, 5002-5011	3.9	1
16	FGFR alterations in urothelial carcinoma: Picking the right target. <i>Bulletin Du Cancer</i> , 2021 , 108, 566-570	2.4	1
15	Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: study protocol for the randomised controlled phase II ReSScue trial. <i>BMJ Open</i> , 2021 , 11, e048541	3	1
14	Development of a Musculoskeletal Ultrasound Protocol to Examine Upper Extremity Rehabilitation Outcomes in Systemic Sclerosis. <i>Journal of Diagnostic Medical Sonography</i> , 2021 , 37, 13-23	0.4	1

13	Clinical and psychosocioeconomic impact of COVID-19 pandemic on patients of the Indian Progressive Systemic Sclerosis Registry (IPSSR). <i>Rheumatology Advances in Practice</i> , 2021 , 5, rkab027	1.1	1
12	Reliability, construct validity and responsiveness to change of the PROMIS-29 in systemic sclerosis-associated interstitial lung disease. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 119, 49-56	2.2	1
11	Management of scleroderma gastrointestinal disease: Lights and shadows.. <i>Journal of Scleroderma and Related Disorders</i> , 2022 , 7, 85-97	2.3	1
10	Reply to Nirmish Singla and Vitaly Margulis@ Letter to the Editor re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018 . The Next Surgical Frontier in Kidney Cancer?	10.2	0
9	American College of Rheumatology guidelines for management of gout. <i>Gout and Nucleic Acid Metabolism</i> , 2013 , 37, 139-146. Exposure is Probably Decisive. <i>European Urology</i> , 2020 , 78, e81-e82		0
8	A Case of Recalcitrant Linear Morphea Responding to Subcutaneous Abatacept. <i>Journal of Scleroderma and Related Disorders</i> , 2021 , 6, 194-198	2.3	0
7	Functional Characterization of Glycoprotein Nonmetastatic Melanoma Protein B in Scleroderma Fibrosis.. <i>Frontiers in Immunology</i> , 2022 , 13, 814533	8.4	0
6	Il buono, il brutto, il cattivo. <i>Thorax</i> , 2014 , 69, 871-2	7.3	
5	Reliability, validity, and responsiveness to change of the Patient-Reported Outcomes Measurement Information System self-efficacy for managing chronic conditions measure in systemic sclerosis.. <i>Journal of Scleroderma and Related Disorders</i> , 2022 , 7, 110-116	2.3	
4	Modulating myofibroblast transition in systemic sclerosis through inhibition of Rho/MRTF regulated transcription (1054.9). <i>FASEB Journal</i> , 2014 , 28, 1054.9	0.9	
3	Current Management of Gout in the U.S : Role of Febuxostat and Other Agents. <i>Gout and Nucleic Acid Metabolism</i> , 2013 , 37, 146		
2	Response to: @iociguat in systemic sclerosis: a potential for disease modification@y Jain and Dhir. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	
1	Association of health-related quality of life (HRQOL) variations with biological biomarkers for patients with metastatic castrate-resistant prostate cancer (MCRPC) treated by abiraterone/prednisone combination or prednisone.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 54-54	2.2	